

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## RPP decision paper

**Review of TA307; Aflibercept in combination with irinotecan and fluorouracil-based therapy for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy**

### Final recommendation post consultation

The guidance should be transferred to the 'static guidance list'.

#### 1. Background

This guidance was issued in March 2014.

At the GE meeting of 9 August 2016 it was agreed that we would consult on the recommendations made in the GE proposal paper. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

#### 2. Proposal put to consultees and commentators

The guidance should be transferred to the 'static guidance' list.

#### 3. Rationale for selecting this proposal

Since the publication of TA307, no significant new evidence has been identified that is likely to lead to a change in the current guidance. It is therefore appropriate to transfer this guidance to the 'static guidance list'.

#### 4. Summary of consultee and commentator responses

Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees.

<p><b>Respondent:</b> Sanofi</p> <p><b>Response to proposal:</b> Agree</p> <p>We agree that there is no new evidence to support remaining on the active list and we are in agreement the topic should be moved to the static list.</p> <p>We understand topics on the static list may be transferred back if new evidence is received that may have an effect on the last guidance issues.</p> <p>We will inform NICE if further evidence is identified to change the current recommendation.</p>	<p><b>Comment from Technology Appraisals</b></p> <p>Comment noted</p>
---	---

**Paper signed off by:** Melinda Goodall, 19/09/2016

**Contributors to this paper:**

Technical Lead: Henry Edwards

Technical Adviser: Joanna Richardson

Programme Manager: Andrew Kenyon